Frequently Asked Questions
The market is segmented based on , By Product (Consumables, Services, Software, Growth Hormone Therapy), Type (Safety, Efficacy, Validation, Protein, Pharmacodynamics, Genetic), Technology (OMICS, Imaging Technology, Immunoassays, Cytogenetics, and Bioinformatics), Service (Sample Preparation, Assay Development, Biomarkers, and Testing), Application (Diagnostics Development, Drug Discovery, and Development, Personalized Medicine, Disease-Risk Assessment, Others), Disease (Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, and Other Diseases), Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Immunological Disorders, Others) – Industry Trends and Forecast to 2030.
.
The Global Cancer Biomarkers Market size was valued at USD 13.24 USD Billion in 2022.
The Global Cancer Biomarkers Market is projected to grow at a CAGR of 13.6% during the forecast period of 2023 to 2030.
The major players operating in the market include F. Hoffmann-La Roche , Thermo Fisher Scientific, Abbott, QIAGEN, PerkinElmer , Merck KGaA, Bio-Rad Laboratories , Enzo Biochem , Charles River Laboratories, Eurofins Scientific, Agilent Technologies , Bruker, Siemens, Epigenomics AG, General Electric
.
The market report covers data from the U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
